Viatris, a global healthcare company, MedAccess, and TB Alliance have announced a new agreement to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34%. Pretomanid is part of two new treatment regimens with high efficacy and shorter treatment durations recently recommended by the World Health Organization (WHO) as the preferred regimens for most drug-resistant tuberculosis patients. Read more here.
top of page
Recent Posts
See AllThe results of the TB-CHAMP trial were recently published. They showed that prophylactic levofloxacin can significantly reduce the risk...
190
This month, the Indian Patent Office denied the last of the three Janssen patent extension applications for bedaquiline. While TB...
100
The Institute of Tropical Medicine has announced two initiatives to honor the legacy of Armand Van Deun: a new meeting room in his name...
560
bottom of page
Comments